Sunday, 23 August 2020

COVID P KZN

 

Ten key points about COVID‐19 in children: The shadows on the wall

First published: 13 August 2020
 
https://doi.org/10.1002/ppul.25025

Abstract

The pandemic of the new coronavirus disease‐2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), initially described in China, is challenging the health care systems of all countries. Every emerging disease raises many questions with a scarcity of answers since all its characteristics are still being discovered. In the case of SARS‐CoV‐2, most of the literature comes from adult patients. Children seem to be less affected. Pediatric patients diagnosed with COVID‐19 disease usually suffer a mild illness, with a low risk of complications, or mortality. Defining the role of children in the transmission of SARS‐CoV‐2 is critical as some national infection control decisions involving children, such as school closures or social distancing, will probably impact the dynamics of the virus. To aid in the knowledge of COVID‐19 in children, this study presents an expert review of the literature published from 1 January to 28 May 2020, including peer‐reviewed and preprint nonpeer‐reviewed studies, along with some relevant articles afterward, summarizing ten key points that characterize the disease in children.

1 BACKGROUND

An outbreak of a new coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was described in Wuhan (China) in December 2019. The first case in a child was reported on 20 January 2020 in Shenzhen (China).1 On 11 March 2020, the WHO declared the new coronavirus disease 2019 (COVID‐19) a pandemic. As of 28 May 2020, more than 350 000 patients have died worldwide.

Most literature has focused on adult disease, but this information might not be transferable to children.2, 3 Diagnostic limitations during the COVID‐19 pandemic and data loss due to low‐quality retrospective studies have probably led to clinicians attending children to use unreliable information. In addition, the recent use of social media permits the sharing of data but might carry a risk of misinformation, disseminating unproven practices. This review is an effort by authors to collect and briefly present published literature in pediatrics to shed light on the topic.

2 METHODS

This expert review was performed by searching published articles through PubMed using the following search terms: COVID‐19, 2019‐nCoV, SARS‐CoV‐2, or novel coronavirus, along with the term child or children. We searched for articles from 1 January to 20 April, 2020 (just 3 months after the first reported case in pediatrics). A total of 243 studies were collected. Two different authors separately (LEG and DAA) screened titles and abstracts for potential eligibility. These eligible articles included patients less than 18 years old, and for those containing descriptions of symptoms, laboratory signs, and radiology features. Only case series with a number of more than 5 were included. Finally, 62 studies were included. Also, a manual search of some references in the selected articles was completed. Due to constant updating, some non‐peer‐reviewed preprint manuscripts were also reviewed. Furthermore, while this review was being written, relevant pediatric papers have been published, which were considered important to be included, increasing the number of included studies to 92. Confidence intervals (CIs) of proportions were calculated using the Wald test included in the Stata version 15, College Station, TX.

3 EPIDEMIOLOGY

The average age reported of COVID‐19 confirmed cases in most countries is around 50 years old, with small differences depending on the demographic characteristics of each country (Figure 1). Most of the data from several countries place the prevalence of confirmed cases in children around 1% to 2% of all diagnosed cases,4, 5 which is strikingly low compared to infections caused by other respiratory viruses. The most recent official report on the epidemiology of COVID‐19 in Spain (18 May 2020), describes among the total notified cases only 0.3% cases in the groups under 10 years old and 0.3% cases in the group 10 to 19 years old.6 Subsequent studies in the late stage of the epidemic in China have suggested a similar transmission in children.7, 8 The data from Iceland offer an accurate view of the age distribution, because the screening included the asymptomatic population.9 This study describes a lower prevalence in population screening in children under 10 years of age compared with adolescents and adults (0/848 [0%] vs 100/12 232 [0.8%], respectively). Targeted diagnosis also showed a parallel trend: 6.7% vs 13.7% confirmed cases among children less than 10 years old and those 10 years of age or older, respectively. This has been similarly reported in a screening study carried out in Vo, a small population next to Padua, Italy.10

image
Figure 1
Open in figure viewerPowerPoint
Age distribution of SARS‐CoV‐2 confirmed cases in different countries. Percentages are calculated from the total of confirmed cases in each country. In the case of the UK, the group aged 80 to 89 includes more than 89 years old. In the case of Iceland, the 0 to 9 group includes 0 to 12 years old; the 10 to 19 group includes 13 to 17 years old; the 20 to 29 group includes 18 to 29 years old. Source: Spain (Spanish Ministry of Health; 26/4/2020), UK (Public Health England; 23/4/2020), Iceland (The Directorate of Health and The Department of Civil Protection and Emergency Management, Iceland; 26/4/2020). SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2 [Color figure can be viewed at wileyonlinelibrary.com]

Seroprevalence studies are being performed in different countries and settings. A preprint study conducted in Geneva (Switzerland) showed an increasing seroprevalence throughout April, from 6.1% to 9.7%.11 The seroprevalence in the 5 to 19‐year‐old group (6.1%) did not differ (P = .12) from that in the 20 to 49‐year‐old group (8.4%). However the first group did not include children under 5 years old, and it included a broad range of ages. A similar study conducted in Spain (ENE‐COVID19 study) between 27 April to 10 May, coordinated by the Spanish Ministry of Health, has shown a global seroprevalence of 5%.12 One of the most interesting aspects of this study is the low seroprevalence among children: the younger the age group, the lower the percentage of seroprevalence (1.1% in <1 year old; 2.2% in 1‐4 years old; 3% in 5‐9 years old; 3.9% in 10‐14 years old, and 3.8% in 15‐19 years old).

In several contact‐tracing studies, children do not seem to be the usual source of infection in most cases.13, 14 Based on the data currently published, it seems that children have not been a major vector for transmission in the current pandemic, but further information is needed to draw clear conclusions. Whether this lower propensity to acquire and transmit the infection is due to biological resistance or due to less exposure is still a question to be answered.

To evaluate the real impact of COVID‐19 among children, screening strategies, including serological studies, are essential, since children usually have nonsevere symptoms or are even asymptomatic, which implies that they are underdiagnosed in studies following targeted diagnosis strategies. These data will be key to determining the role of children in the transmission of SARS‐CoV‐2 and, as a consequence, adopting decisions regarding nonpharmacologic preventive approaches.

To summarize, the prevalence of COVID‐19 disease in children is lower than in adults. Although initially children were supposed to have a relevant role in the transmission of the infection, several studies suggest that they do not have such an important position.

4 SYMPTOMS

Clinical features seem to be mild in comparison with adults.15 At the time of writing, at least 3473 COVID‐19 cases had been reported in children (Table 1), but detailed data remain scarce. The best‐established features are the presence or absence of fever and cough, but these have only been recorded in 31% of children in case reports. Fever is the most frequent symptom (58.3%), followed by cough (47.3%) and sore throat (18.3%). Rhinorrhea (15.9%) and gastrointestinal symptoms (12.7%) are also frequent. Some data in adults have established fever (71%‐83%) and cough (65%‐80%) as the most commonly reported symptoms.15, 16 Other symptoms in adults, such as headaches or myalgia, are not usually reported in children. Non‐mild disease (defined as pneumonia or need for hospitalization) or a more severe illness accounted for 33.3% and 9.1% of all the cases reported, respectively, in this review.

Table 1. Case series of COVID‐19 in pediatric patients. Symptoms, laboratory and radiology features. Update: May 24, 2020
AuthorsWei16Feng17Chen18Cai19Zhou20Wang21Xia22Tang23Liu24Xu25Zhang26Lu27Sun28
Na91531109312026610341718
Symptoms
Fever4/7b514742012116626716
Cough2/7113621413126520836
Sore throatND024021NDND4ND79ND
Rhinorrhea2/712221232ND2ND13ND
GastrointestinalND02ND0352424155
Non‐mild disease0/712124414201850ND1118
Severe or critical0/7000001010ND48
Chronic diseaseNDNDNDNDNDND700ND4ND1
Laboratory
LymphocytosisNDND1716ND3250017ND2
LymphocytopeniaNDND00027140061
Normal CRPNDND277ND27/301121ND10141383
High PCTNDNDND0ND1/28160ND501055
Radiology
Chest X‐ray
NormalNDNDND6NDNDND8ND10NDNDND
Unilateral opacitiesNDNDND4NDNDND11ND0NDNDND
Bilateral opacitiesNDNDND0NDNDND7ND0NDNDND
Chest CT
NormalND620ND117481/510660/1690
Unilateral opacitiesNDND8NDNDND611001432/1692
Bilateral opacitiesNDND3NDNDND1074/501477/1696
AuthorsShen29Zhu30Zheng31Qiu32Su33USA CDC15Tagarro5UK RCPCH34Parri35Garazzino36Shekerdemian37TOTAL
Na9102536925724183100168483473
SymptomsPROPORTION (%)CI, 95%
Fever3413132163/291ND61/7654138ND643/1102 (58.3)55.4 − 61.2
Cough131171158/291ND31/764482ND521/1102 (47.3)44.3 − 50.2
Sore throat10ND2071/291ND3/7649ND182/996 (18.3)16.0 − 20.7
Rhinorrhea0ND2ND021/291ND20/762245ND160/1008 (15.9)13.7 − 18.2
Gastrointestinal2032037/291ND11/761031ND138/1086 (12.7)10.8 − 14.8
Non‐mild disease2517190147/74525ND213334511/1535 (33.3)30.9 − 35.6
Severe or critical01200NDNDND2163368/749 (9.1)7.2 − 11.3
Chronic diseaseNDND2NDND80/3451132/76273340237/897 (26.4)23.6 − 29.4
Laboratory
Lymphocytosis2215ND1NDNDNDNDNDND91/207 (44.0)37.3 − 50.7
Lymphocytopenia0010112NDNDND14/57NDND58/331 (17.5)13.8 − 21.9
Normal CRP710ND359NDNDNDND74/121ND393/525 (74.8)70.9 − 78.3
High PCTND0/8ND60NDNDND4/23NDND142/383 (37.1)32.3 − 42.0
Radiology
Chest X‐ray
NormalNDNDNDNDNDNDNDND15/35NDND39/81 (48.1)37.6 − 58.8
Unilateral opacitiesNDNDNDNDNDNDNDND6/35NDND21/42 (50.0)d35.5 − 64.4
Bilateral opacitiesNDNDNDNDNDNDNDND14/35NDND21/42 (50.0)d35.5 − 64.4
Chest CT
Normal758175NDNDNDNDNDND175/447 (39.1)34.7 − 43.7
Unilateral opacities235ND1NDNDNDNDNDND84/222 (37.8)d31.7 − 44.3
Bilateral opacities0212ND3NDNDNDNDNDND138/222 (62.2)d55.6 − 68.2
  • Note: Symptoms, laboratory, and radiology features. Update: 24 May 2020.
  • Abbreviations: CDC, Centers for Disease Control and Prevention (US); CI, confidence interval; CRP, C‐reactive protein; CT, computed tomography; GI, gastrointestinal; RCPCH, Royal College of Pediatrics and Child Health (UK); ND, no data; PCT, procalcitonin.
  • a Only case series with N > 5 are included in this table.
  • b A fraction means that there is no available data for the total N in the case series.
  • c Non‐mild disease includes a presentation as pneumonia in case reports from China and Italy (Parri and Garazzino) and the need for hospitalization in CDC and Tagarro reports. Severe or critical cases are also included in those characterized as a non‐mild disease.
  • d Percentages are calculated from the total cases with abnormal chest X‐ray or abnormal computed chest tomography, respectively.

Notably, some singular presentations that could be associated with SARS‐CoV‐2 infection have been described in children, such as infection‐induced chilblains39 in adolescents and young adults. By mid‐April, an increase in episodes similar to Kawasaki disease and/or toxic shock syndrome was reported in several countries (eg, UK, US, France, Italy, or Spain). It was initially named Pediatric multisystem inflammatory syndrome (PIMS) temporally associated with COVID‐19 by the Royal College of Paediatrics and Child Health (RCPCH).40 Due to the temporal coincidence with the SARS‐CoV‐2 pandemic an association with COVID‐19 has been proposed. The Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC), WHO, and RCPCH have published their own case definitions.40, 43 The main characteristics of the case series published to date are shown in Table 2.44, 48

Table 2. Case series (n > 5) describing pediatric inflammatory multisystem syndrome temporally associated with COVID‐19
Verdoni et al44Belhadjer et al45Riphagen et al46Toubiana et al47Chiotos et al48
n = 10n = 35n = 8n = 17n = 6
CountryItalyFrance and SwitzerlandUKFranceUS
Date of diagnosis18/2‐20/04/202022/03‐30/4/202010 d in mid‐April, 202027/4‐7/5/2020ND
Age, median (range)7.3 (2‐16)10 (2‐16)8 (4‐14)7.5 (3‐16)7.5 (5‐14)
Sex (male)7 (70%)18 (51%)5 (63%)7 (42%)1 (17%)
Symptoms
Fever10 (100%)35/35 (100%)8 (100%)17 (100%)7 (100%)
Rash7 (70%)20 (57%)4 (50%)13 (76%)2 (33%)
Abdominal painNDND6 (75%)17 (100%)3 (50%)
Vomiting/diarrhea6 (60%)29 (83%)7 (88%)16 (94%)5 (83%)
Intensive care
Shock5 (50%)28 (80%)8 (100%)11 (65%)6(100%)
Cardiac involvement6 (60%)35 (100%)7 (88%)12 (71%)a5 (83%)
Inotrope support2 (20%)28 (80%)8 (100%)10 (59%)5 (83%)
Mechanical ventilationND22 (62%)ND10 (59%)3 (50%)
Mortality0 (0%)0 (0%)1 (13%)0 (0%)0 (0%)
SARS‐CoV‐2
Positive PCRb2 (20%)12 (34%)2 (25%)7 (41%)3 (50%)
Positive serology8 (80%)30 (86%)8 (100%)14 (88%)5/5 (100%)
  • Note: Cardiac involvement: coronary aneurism, ejection fraction decreased, mitral valve regurgitation, or pericardial effusion.
  • Abbreviations: COVID‐19, coronavirus disease‐2019; ND, not described; PCR, polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
  • a Considered as myocarditis.
  • b SARS‐CoV‐2 PCR from nasopharyngeal/oropharyngeal swab.

To date, some cases of neonatal SARS‐CoV‐2 infection have been reported.49, 50 Most were asymptomatic or had mild symptoms, but some cases progressed to a severe infection.51, 52 The earliest diagnosed patient using molecular diagnosis from a nasopharyngeal specimen was a 36‐hour‐old newborn.53 Breastfeeding has not been discouraged by most scientific societies (eg, WHO, UNICEF, Spanish Society of Neonatology, or Academy of Breastfeeding Medicine). To note, recently the detection of SARS‐CoV‐2 in human breast milk by RT‐PCR has been published, which deserves further studies.54

Some questions about vertical transmission have been raised after the publication of three newborns born to mothers with SARS‐CoV‐2 infection who presented positive IgM against SARS‐CoV‐2 at birth, but a negative SARS‐CoV‐2 PCR,55, 56 and the detection of SARS‐CoV‐2 RNA in the placenta of pregnancies with COVID‐19.57 However, these data should be interpreted with caution.

In summary, pediatric patients with a SARS‐CoV‐2 infection usually develop mild disease. However, the increasing number of patients with PIMS, who usually have a severe presentation, deserves a detailed analysis to establish the best definition and treatment. Regarding vertical transmission, currently, there is not enough information and further studies are needed.

5 LABORATORY

Typical COVID‐19 laboratory markers in adults are not prevalent in children, but the vast majority (Table 1) do not document information about laboratory tests, so inaccurate extrapolation from adult literature is frequent. Leukocyte counts are often normal, but lymphocytosis is frequent (44%) in children with COVID‐19. Lymphocytopenia has been reported as the most common sign in blood count for adults,58, 59 but it is only present in 17.5% of children. It has been related to poorer prognosis in adults, so perhaps the low prevalence in our review might be explained by a high frequency of mild cases (66.7% in this review). Procalcitonin levels seem to be greater (37.1%) than adults but reference ranges were not clearly defined. C‐reactive protein is within the normal range in about 74.8% of children, but in contrast, it remained normal in only 37.5% (3/8 cases) of children requiring intensive care.29 Liver enzymes are frequently normal in pediatric patients,20, 23, 26 in contrast to adults. Remarkably, 50% of children in a case series of severe and critically ill patients presented abnormal liver function.29 Other typical markers in adults such as high lactate dehydrogenase, ferritin, D‐dimer, or interleukin‐6 are not evident in children but may be altered in severe and critical patients. In our experience, from 43 confirmed pediatric cases who underwent a blood test, 30% presented lymphocytes below 1200/mm3 and 70% a D‐dimer above 700 mg/dL.60

So, some analytical markers to take into account when evaluating a child with confirmed or suspected COVID‐19, are lymphocyte count, D‐dimer, C‐reactive protein, procalcitonin, and liver enzymes. However, their cutoff points in COVID‐19 and the association with severe disease is not as well defined as in adults.

6 RADIOLOGY

Most data in children are provided by computed chest tomography (CCT) studies from China (Table 1). From our perspective, it is surprising that CCT has become the COVID‐19 gold standard in radiology diagnosis in children in some regions as radiation concerns might exist with doubtful medical benefit. In Spain, CCT is not recommended by pediatric guidelines in mild and moderate COVID‐19.61 Few data are available from chest radiographs in children with COVID‐19. No abnormalities in radiographs are shown in 48.1% of cases. Unilateral or bilateral infiltrates in CCT are found in 60.9% of children. Bilateral ground‐glass opacities are the most prevalent findings. In addition, patchy shadows and consolidations are frequent.

7 MICROBIOLOGICAL DIAGNOSIS

Accurate and reliable diagnosis of SARS‐CoV‐2 infections remains the cornerstone of the public health strategy for disease containment. The virus nucleic acid real time‐polymerase chain reaction (RT‐PCR) test has become the current standard diagnostic method, using specimens collected via nasopharyngeal swab.53 Most patients have high viral loads in upper respiratory specimens soon after symptom onset which peak in the first few days before declining.54 A study including 57 children showed that symptomatic infants had higher nasopharyngeal SARS‐CoV‐2 viral loads (measured as cycle threshold) than older children.55 Recent data from a German study indicate that viral loads in the very young (age group 0‐6 years) do not significantly differ from those of adults.62 Whether these results are associated with different time points of testing during the infection or with host biology peculiarities deserves further analysis.

Lower respiratory tract secretions, such as bronchoalveolar lavage fluid or bronchial aspirate, are more sensitive for diagnosis,48 and should be tested in undiagnosed critically ill children with pneumonia. In newborns born to mothers with SARS‐CoV‐2 infection a combined throat/nasopharynx, PCR should be done first at 24 hours of age and again at 48 hours of age. Some infants have had a negative test at 24 hours only to have a positive test at a later time.63

However, there are some limitations regarding nucleic acid tests, including low throughput and high rates of false‐negative results. These may be caused by a very early or late collection of the sample, inadequate or insufficient viral material in the specimen, laboratory error during sampling, or restrictions on sample transportation.57 So, if a negative result is obtained from a child with a high index of suspicion for COVID‐19 virus infection the patient should be retested.

Detection of specific serum antibodies for SARS‐CoV‐2 by automated chemiluminescence immunoassays or enzyme‐linked immunosorbent assays, could provide an alternative solution and compensate for the limitations of the RT‐PCR, especially in the late stages of the disease. The majority of children with the multisystem inflammatory syndrome have serologic evidence of infection, but approximately a third or fewer tested positive for SARS‐CoV‐2 by PCR.45

To put it briefly, SARS‐CoV‐2 PCR of the nasopharyngeal swab is considered the gold standard diagnostic test for acute COVID‐19 disease. However, due to its suboptimal sensitivity, a retest of the same specimen or even invasive specimens may be considered for nonconfirmed cases. On the other hand, SARS‐CoV‐2 serology has a relevant diagnostic role in the late stages of the disease, including PIMS, or for seroprevalence studies.

8 COINFECTIONS

Children with COVID‐19 might be coinfected with other respiratory viruses and bacteria. Few case series in children have reported relevant data on this topic. Remarkably, two different studies found that 40% to 50% of pediatric patients were coinfected. Influenza virus and Mycoplasma pneumoniae were the most frequently documented pathogens. In addition, respiratory syncytial virus (RSV), parainfluenza, adenovirus, Epstein‐Barr virus, or cytomegalovirus have been described.23, 27, 64 Also, Jiang et al65 documented two children with SARS‐CoV‐2 confection with human metapneumovirus (2/2), RSV (1/2), and Mycoplasma (1/2). In contrast, other case series did not document coinfections with respiratory viruses such as influenza, parainfluenza or RSV.20, 26 The clinical relevance of coinfections is an issue that may have important implications.

9 COMORBIDITIES

At the time of writing this article, 12 studies have recorded information on underlying conditions, which is less than 26% of the total patients in this review. Among patients with reliable information, 26.4% had at least one comorbidity. The CDC in 6 April 2020 reports established that chronic lung disease (including asthma) is the most prevalent preexisting condition (50%), followed by cardiovascular disease (31%) and immunosuppression (12.5%). In addition, a study highlighted that 40/48 (83%) patients less than 21 years old admitted to a pediatric intensive care unit (PICU) had significant preexisting comorbidities.38

Of note, immunosuppressive therapy has not been linked to poorer prognosis in small pediatric case series. D'Antiga66 described three children in a postliver transplant period positive for SARS‐CoV‐2 with mild disease and absence of lung affection in Lombardia (Italy). Turner et al67 focused on children affected by inflammatory bowel disease on immunosuppression and described eight cases of COVID‐19 in these children who only experienced mild symptoms. Melgosa et al68 described 16 children with chronic renal pathologies diagnosed with COVID‐19 in Spain. Of these, six had end‐stage kidney disease (three transplant recipients and three on chronic hemodialysis), and the severity was mild in all the patients.

Balduzzi et al69 have described an Italian cohort of 5 children with malignancy positive for SARS‐CoV‐2. All patients recovered from a mild course.69 However, there are insufficient and controversial data in children with hematology‐oncology malignant diseases. Sun et al29 describe the clinical features of severe pediatric patients requiring intensive care. One out of three critical children in this study was suffering acute lymphocytic leukemia when infected with COVID‐19. A flash survey circulated on 16 March 2020 involving reports of children on anticancer treatment from 25 countries collected only nine cases of COVID‐19, including eight children with asymptomatic or mild disease and one who had just been diagnosed.70 A multicenter study involving all pediatric oncology units in Madrid (Spain) calculated a COVID‐19 prevalence of 1.3% (15 confirmed cases) among children with cancer.71 The clinical characteristics were milder than those described in adult patients with cancer. On the other hand, as of 16 April 2020, there were 33 confirmed COVID‐19 cases from French pediatric oncology centers, of which five (15%) were admitted to PICU.72 There were no fatal cases at the time of publication.

In summary, comorbidities in children do not appear to be a relevant risk factor among children with COVID‐19 in studies focused on cohorts of children with specific chronic conditions. However, as is shown below, a relevant percentage of children with COVID‐19 admitted to PICU have some comorbidity. Anyway, due to the vulnerability of patients with chronic conditions, a special caution seems to be recommended when attending these children during SARS‐CoV‐2 epidemics.

10 SEVERE AND CRITICAL CASES

The vast majority of symptomatic children recover from COVID‐19 within 1 to 2 weeks. In contrast to adults, severe COVID‐19 infection in children is not frequent. Some of the proposed hypotheses as to why there is different severity among children compared with adults are73, 74: (a) different angiotensin‐converting enzyme 2 expressions in cell membranes75; (b) better control of viral replication through innate immunity; (c) different inflammatory signaling pathways; (d) preexisting immunity to common coronaviruses76; (e) differences in clotting function; and (f) lower comorbidities. However, none of these hypotheses has been validated.

A study from China included 2143 children with microbiology‐confirmed (34%) or clinically suspected COVID‐19 (66%). Severe (defined as hypoxic) or critical cases were documented in 5.8% and 2.8% of the total SARS‐CoV‐2 confirmed patients, respectively. Children aged less than 1 year had the highest prevalence of severe and critical disease (10.6%), and 53% of children in PICUs were infants. However, as a limitation, this group had the highest proportion of clinically suspected disease, so other viruses may have led to severe disease. Of note, children aged 1 to 5 years might have a poorer prognosis (7.3% had the severe and critical disease) compared with children more than 5 years, and adolescents (3%‐4.2%).

The CDC report included prognostic information, but hospitalization status was declared in only 29% of children.15 Hospitalization was more frequent among children aged less than 1 year and 5.2% of infants required intensive care admission. In addition, 33% of children in intensive care units were aged less than 1 year. Patients with underlying conditions also required more frequent hospitalization than healthy children. Out of hospitalized patients, 77% were children with chronic conditions which stand in contrast to 12% of non‐hospitalized COVID‐19 infected children.

Information on children with COVID‐19 requiring intensive care is scarce and incomplete. Deterioration starts typically after 7 to 10 days of clinical course. Some previously described clinical case series in this review documented children needing admission to PICU 5, 25, 28, 29, 32 but most series did not. Liu et al25 reported 6 children and 1 patient 3 years of age that required intensive care. Lu et al28 included 171 children with confirmed SARS‐CoV‐2 infection, and three required intensive care. All three had comorbidities. A 14‐year‐old adolescent with intussusception died of multiple organ failure. Zheng et al32 described 25 children with COVID‐19, and two of them required PICU admission and invasive mechanical ventilation (IMV). Remarkably, both patients were infants and had congenital heart diseases. At the time of publishing that paper no deaths were reported. Also, a Spanish report described 41 children affected by COVID‐19 disease, of whom four were transferred to PICU.5 Only one patient required IMV and no deaths were reported.

Sun et al29 described a case series of eight children with COVID‐19 focused on those requiring intensive care. All patients were admitted with tachypnea, but only 6/8 had fever and cough. Of note, only one patient had preexisting conditions. Two patients underwent IMV. A cytokine storm was common in these patients and especially in those critically ill. A multicenter study involving 46 PICU located in the US and Canada included 48 confirmed COVID‐19 infections between 14 March and 3 April 2020.38 Respiratory symptoms were the most common presentation (73% of all cases), with 18 (38%) cases requiring IMV. At the time of publishing that study, two patients (4%) had died and 15 (31%) were still hospitalized.

So, although severe disease is not common in children with COVID‐19, some patients develop a clinical deterioration that requires intensive care. A retrospective view of the pandemic in children shows two different periods in the manifestations of COVID‐19 severe disease in children: a first period during the first weeks of the pandemic, with respiratory failure as the main manifestation, and a second period, 2 to 4 weeks after the peak of incidence, with patients developing PIMS with hemodynamic dysfunction.

11 MORTALITY

Many asymptomatic or mildly symptomatic patients are not microbiologically confirmed nor reported, so caution is required when analyzing prognostic data in children.

The global case fatality rate in adults has been established at 4%, but many geographical variations have been established. As far as we know, by 27 April, at least 22 children and adolescents (<18 years old) had died from COVID‐19 (2 in China, 1 in Italy, 6 in Spain, 3 in the US, 8 in the UK, and 2 in Colombia), but an official global data source focusing on pediatric cases at the time of writing is not available. Regarding PIMS, as of 11 May, five fatality cases have been reported (1 in France, 1 in the UK, and 3 in the US).42

12 TREATMENT

Currently, the main treatment for COVID‐19 disease is supportive care, ensuring adequate oxygenation and nutritional support for the patient. The specific treatment has focused on two different strategies77: (a) antiviral treatment aimed at controlling viral replication, which could be useful mainly in early stages of the infection and (b) immunomodulatory treatment to control the deleterious effects of an excessive inflammatory response, which occurs in the intermediate and late stage of the disease. To note, experience and knowledge of pharmacokinetics in some of these drugs are scarce in children. For this reason, it is convenient to make rational use of the drugs under study, assessing the risk‐benefit individually. Some national pediatric societies have published clinical guidelines on the treatment of COVID‐19 in children.61, 78 The Spanish Society of Pediatrics has proposed specific treatments according to the severity and risk factors of the patient, highlighting a cautious approach (Table 3).61

Table 3. Proposed management of COVID‐19 in children
SeverityChest X‐rayTreatmentManagement
Mild: No hypoxemia, no distress, or mild distressNot indicated except for risk groupsSupportive care (1) (2)Discharge at home except for risk groups (individualize)
Moderate: Hypoxemia or moderate distressNo signs of lung infectionSupportive care (1)Hospital admission without antiviral treatment (2)
Signs of lung infectionSupportive care (1)Hospital admission
Consider systemic steroids if hypoxemia
Consider the compassionate use of remdesivir (2)
Severe (ICU): Severe hypoxemia, severe distress, or hemodynamic dysfunctionSigns of lung infectionSupportive care (1)Hospital admission
Consider the compassionate use of remdesivir (2)
Consider systemic steroids and/or tocilizumab
  • Note: Adapted from the Guidance of The Clinical Management of Pediatric Patients with SARS‐CoV‐2 Infection from the Spanish Society of Pediatrics.61 (1) Consider empirical antibiotic therapy if bacterial coinfection is suspected. (2) Consider the use of antimicrobials against SARS‐CoV‐2 other than remdesivir only in the context of clinical trials.
  • Abbreviations: COVID‐19, coronavirus disease‐2019; ICU, intensive care unit; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.

Regarding the antiviral treatments proposed, they target different stages of the viral replication cycle.79 Among antimicrobials 77 (eg, lopinavir/ritonavir, chloroquine/hydroxychloroquine, or ivermectin),  only remdesivir has proved to be of clinical benefit in a clinical trial including patients more than or equal to 18 years old.80 In terms of anti‐inflammatory drugs, some guidelines have included systemic steroids to be considered for COVID‐19 disease.81 Tocilizumab, an anti‐IL‐6 antibody, is being evaluated in several studies.82 Currently, some clinical trials are evaluating different drugs in children: hydroxychloroquine in PanCOVID19 trial (EudraCT2020‐001156‐18) or remdesivir in children more than or equal to 12 years old (NCT04292730).

Consequently, until specific evidence on the best pharmacological approach for COVID‐19 in children is developed, supportive care continues to be the backbone of the management. Depending on the stage of the disease, antiviral treatment, or immunomodulatory drugs may be considered, always balancing the individual's risk to benefit ratio.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)